Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors.

Cyclooxygenase (COX), known to exist in two isoforms, COX-1 and COX-2, is a key enzyme in prostaglandin synthesis and the target for most nonsteroidal anti-inflammatory drugs. In this study, we show that human T lymphocytes express the COX-2 isoenzyme. COX-2 mRNA and protein were induced in both Jurkat and purified T cells stimulated by TCR/CD3 or PMA activation. COX-2 mRNA was induced very early after activation and superinduced by protein synthesis inhibitors, whereas it was inhibited by the immunosuppressive drug cyclosporin A, identifying it as an early T cell activation gene. Interestingly, treatment with COX-2-specific inhibitors such as NS398 or Celecoxib severely diminished early and late events of T cell activation, including CD25 and CD71 cell surface expression, IL-2, TNF-alpha, and IFN-gamma production and cell proliferation, but not the expression of CD69, an immediate early gene. COX-2 inhibitors also abolished induced transcription of reporter genes driven by IL-2 and TNF-alpha promoters. Moreover, induced transcription from NF-kappaB- and NF-AT-dependent enhancers was also inhibited. These results may have important implications in anti-inflammatory therapy and open a new field on COX-2-selective nonsteroidal anti-inflammatory drugs as modulators of the immune activation.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.

[3]  J. Gómez-Reino,et al.  Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. , 1998, British journal of rheumatology.

[4]  B. Boneu,et al.  Arachidonic acid enhances the tissue factor expression of mononuclear cells by the cyclo-oxygenase-1 pathway: beneficial effect of n-3 fatty acids. , 1998, Journal of immunology.

[5]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[6]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[7]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[8]  J. Bernal,et al.  Thyroid Hormone‐Regulated Expression of RC3/Neurogranin in the Immortalized Hypothalamic Cell Line GT1‐7 , 1997, Journal of neurochemistry.

[9]  Hall Vc,et al.  Effects of tenidap and nonsteroidal antiinflammatory drugs on the response of cultured human T cells to interleukin 2 in rheumatoid arthritis. , 1997 .

[10]  J. Lee,et al.  Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. , 1997, Journal of immunology.

[11]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[12]  R. Scorza,et al.  Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[13]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[14]  Moulton Pj INFLAMMATORY JOINT DISEASE : THE ROLE OF CYTOKINES, CYCLOOXYGENASES AND REACTIVE OXYGEN SPECIES , 1996 .

[15]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[16]  J. Adams,et al.  Constitutive cyclooxygenase (COX‐1) and inducible cyclooxygenase (COX‐2): Rationale for selective inhibition and progress to date , 1996, Medicinal research reviews.

[17]  H. Sheng,et al.  G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. , 1996, Cancer research.

[18]  H. Herschman Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.

[19]  W. Fung-Leung,et al.  Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac‐1 and E‐selectin expression , 1996, European journal of immunology.

[20]  F. Breedveld,et al.  Tenidap, but not Nonsteroidal Anti‐Inflammatory Drugs, Inhibits T‐Cell Proliferation and Cytokine Induction , 1995, Scandinavian journal of immunology.

[21]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[22]  J. Otto,et al.  Different Intracellular Locations for Prostaglandin Endoperoxide H Synthase-1 and −2 (*) , 1995, The Journal of Biological Chemistry.

[23]  Lubing Zhou,et al.  Suppression of NFκB activation and NFκB‐dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5‐lipoxygenase , 1995 .

[24]  M. Fresno,et al.  Biphasic control of nuclear factor‐χB activation by the T cell receptor complex: role of tumor necrosis factor α , 1995 .

[25]  D. Ritchie,et al.  Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. , 1994, Journal of immunology.

[26]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[27]  M. Fresno,et al.  Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. , 1994, Journal of immunology.

[28]  U. Das,et al.  Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. , 1994, Prostaglandins, leukotrienes, and essential fatty acids.

[29]  Dan R. Littman,et al.  Signal transduction by lymphocyte antigen receptors , 1994, Cell.

[30]  C. Thiemermann,et al.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Quesniaux Immunosuppressants: Tools to investigate the physiological role of cytokines , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  W. M. Weaver,et al.  Two essential regulatory elements in the human interferon gamma promoter confer activation specific expression in T cells , 1993, The Journal of experimental medicine.

[33]  S. Higuchi,et al.  Selective inhibition of NS‐398 on prostanoid production in inflamed tissue in rat carrageenan‐air‐pouch inflammation , 1993, The Journal of pharmacy and pharmacology.

[34]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[35]  J. Economou,et al.  The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. , 1992, The Journal of biological chemistry.

[36]  M. Mattei,et al.  Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin synthase/cyclooxygenase activity. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[37]  V. Winn,et al.  cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. L. Roper,et al.  A new view of prostaglandin E regulation of the immune response. , 1991, Immunology today.

[39]  K. Seibert,et al.  Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. , 1990, The Journal of clinical investigation.

[40]  T. Hla,et al.  Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. , 1990, The Journal of biological chemistry.

[41]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[42]  T. Kawakami,et al.  Coordinate expression of src family protooncogenes in T cell activation and its modulation by cyclosporine. , 1990, Journal of immunology.

[43]  M. Goldyne Eicosanoid metabolism by lymphocytes: do all human nucleated cells generate eicosanoids? , 1989, Pharmacological research.

[44]  M. Goldyne Lymphocytes and arachidonic acid metabolism. , 1988, Progress in allergy.

[45]  S. Nordeen,et al.  Luciferase reporter gene vectors for analysis of promoters and enhancers. , 1988, BioTechniques.

[46]  G. Crabtree,et al.  Characterization of antigen receptor response elements within the interleukin-2 enhancer , 1988, Molecular and cellular biology.

[47]  A. Israël,et al.  Purification of KBF1, a common factor binding to both H‐2 and beta 2‐microglobulin enhancers. , 1987, The EMBO journal.

[48]  P. Golstein,et al.  Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester , 1985, Nature.

[49]  M. Goldyne,et al.  In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. , 1980, Prostaglandins.

[50]  M. Caton,et al.  Prostaglandins and thromboxanes. , 1979, Progress in medicinal chemistry.

[51]  R. Bockman,et al.  Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages , 1978, The Journal of experimental medicine.

[52]  S. Kivity,et al.  Leukotrienes , 1998, Springer Netherlands.

[53]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[54]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[55]  D. Dewitt,et al.  Prostaglandin endoperoxide H synthases-1 and -2. , 1996, Advances in immunology.

[56]  D. Munroe,et al.  Novel intracellular signaling function of prostaglandin H synthase-1 in NF-kappa B activation. , 1995, Journal of inflammation.

[57]  A. Rao,et al.  Transcriptional regulation of the IL-2 gene. , 1995, Current opinion in immunology.

[58]  S. Higuchi,et al.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. , 1994, Prostaglandins.

[59]  K. Resch,et al.  Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. , 1994, Kidney international.

[60]  J. Adams,et al.  Differentiation in vivo of classical non-steroidal antiinflammatory drugs from cytokine suppressive antiinflammatory drugs and other pharmacological classes using mouse tumour necrosis factor alpha production. , 1993, Drugs under experimental and clinical research.

[61]  P. Linsley,et al.  The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.

[62]  S. Schreiber,et al.  The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.

[63]  H. Herschman Primary response genes induced by growth factors and tumor promoters. , 1991, Annual review of biochemistry.

[64]  G. Crabtree,et al.  Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. , 1990, Annual review of immunology.

[65]  T. Mustelin,et al.  Molecular events mediating T cell activation. , 1990, Advances in immunology.

[66]  J. Goodwin Immunomodulation by eicosanoids and anti-inflammatory drugs. , 1989, Current opinion in immunology.